Draflazine is a synthetic small‑molecule drug best known as a high‑affinity inhibitor of the equilibrative nucleoside transporter 1, first explored as a cardiotonic/adenosine reuptake inhibitor and later investigated for inflammatory bowel disease indications including ulcerative colitis. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include (S)-Draflazine, Draflazina and Draflazinum. Its PubChem CID is 60849.
Draflazine
| CAS No | 120770-34-5 |
|---|---|
| Molecular Formula | C30H33Cl2F2N5O2 |
| Molecular Weight | 604.5 g/mol |
| Synonyms | 1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Draflazine is a synthetic small‑molecule drug best known as a high‑affinity inhibitor of the equilibrative nucleoside transporter 1, first explored as a cardiotonic/adenosine reuptake inhibitor and later investigated for inflammatory bowel disease indications including ulcerative colitis.
The listed CAS number is 120770-34-5.
The listed molecular formula is C30H33Cl2F2N5O2.
The listed molecular weight is 604.5 g/mol.
1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide.
The source lists (S)-Draflazine, Draflazina and Draflazinum.